Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ITRM
$0.328
$-0.0154
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Next Earnings
2026-01-11
Beta
2.862
Average Volume
1034674
Market Cap
17329946
Last Dividend
0
CIK
0001659323
ISIN
IE000TTOOBX0
CUSIP
G6333L101
CEO
Corey N. Fishman
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
9
IPO Date
2018-05-25
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Iterum Therapeutics Provides Business Update | DUBLIN and CHICAGO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH™'s market access continues to accelerate. | GlobeNewsWire | 2025-12-23 08:00:00 |
| Iterum Therapeutics Provides Business Update | DUBLIN and CHICAGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH™'s market access continues to accelerate. | GlobeNewsWire | 2025-12-17 08:00:00 |
| Iterum Therapeutics Provides Business Update | DUBLIN and CHICAGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. | GlobeNewsWire | 2025-12-05 08:00:00 |
| Iterum Therapeutics Provides Business Update | DUBLIN, Ireland and CHICAGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Specialty Distributor Now Stocked: ORLYNVAH™ is now available at McKesson, which will allow certain physicians the ability to procure the product directly from McKesson through this specialty distribution channel, consistent with their practice preferences. | GlobeNewsWire | 2025-11-24 08:00:00 |
| Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript | Iterum Therapeutics plc ( ITRM ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Kevin Dalton Corey Fishman - President, CEO & Director Christine Coyne - Chief Commercial Officer Judith Matthews - Chief Financial Officer Conference Call Participants Antonio Arce - WestPark Capital, Inc. Jason Mccarthy - Maxim Group LLC, Research Division Presentation Operator Hello, and welcome, everyone, to the Interim Therapeutics Third Quarter 2025 Financial Results. My name is Becky and I will be your operator today. | Seeking Alpha | 2025-11-14 11:11:34 |
| Iterum Therapeutics Reports Third Quarter 2025 Financial Results | - -Commercially Launched ORLYNVAH ™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. “We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs),” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. | GlobeNewsWire | 2025-11-14 07:00:00 |
| Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 | DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Friday, November 14, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. | GlobeNewsWire | 2025-11-07 08:00:00 |
| Iterum Therapeutics to Present Data at IDWeek 2025 | DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America's IDWeek 2025 conference taking place in Atlanta, GA from October 19-22, 2025. | GlobeNewsWire | 2025-10-14 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| DEF 14A | 2026-01-02 | 2026-01-02 | View Filing |
| PRE 14A | 2025-12-23 | 2025-12-23 | View Filing |
| 8-K | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-11-20 | 2025-11-20 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-10-16 | 2025-10-16 | View Filing |
| 424B5 | 2025-10-16 | 2025-10-16 | View Filing |
| 8-K | 2025-09-10 | 2025-09-10 | View Filing |
| 8-K | 2025-08-28 | 2025-08-28 | View Filing |
| 8-K | 2025-08-20 | 2025-08-20 | View Filing |
| 4 | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-08-04 | 2025-08-04 | View Filing |
| DEF 14A | 2025-07-29 | 2025-07-28 | View Filing |
| 8-K | 2025-07-18 | 2025-07-18 | View Filing |
| PRE 14A | 2025-07-18 | 2025-07-18 | View Filing |
| 4 | 2025-07-03 | 2025-07-03 | View Filing |
| 3 | 2025-07-03 | 2025-07-03 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| 8-K | 2025-05-19 | 2025-05-19 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-04-30 | 2025-04-29 | View Filing |
| 424B5 | 2025-04-30 | 2025-04-29 | View Filing |
| 3 | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-10 | 2025-03-10 | View Filing |
| EFFECT | 2025-02-20 | 2025-02-20 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-02-14 | 2025-02-14 | View Filing |
| S-3 | 2025-02-07 | 2025-02-07 | View Filing |
| 10-K | 2025-02-07 | 2025-02-07 | View Filing |
| 8-K | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 8-K | 2024-12-11 | 2024-12-11 | View Filing |
| 424B5 | 2024-12-10 | 2024-12-10 | View Filing |
| 8-K | 2024-11-21 | 2024-11-21 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-01 | 2024-11-01 | View Filing |
| 424B5 | 2024-10-30 | 2024-10-30 | View Filing |
| 424B5 | 2024-10-28 | 2024-10-28 | View Filing |
| 8-K | 2024-10-25 | 2024-10-25 | View Filing |
| 8-K | 2024-10-15 | 2024-10-15 | View Filing |
| 424B5 | 2024-10-11 | 2024-10-11 | View Filing |
| 8-K | 2024-10-08 | 2024-10-08 | View Filing |
| 8-K | 2024-10-04 | 2024-10-04 | View Filing |
| DEFA14A | 2024-09-30 | 2024-09-30 | View Filing |
| DEFA14A | 2024-09-30 | 2024-09-30 | View Filing |
| DEFA14A | 2024-09-24 | 2024-09-24 | View Filing |
| DEFA14A | 2024-09-24 | 2024-09-24 | View Filing |
| DEFA14A | 2024-09-23 | 2024-09-23 | View Filing |
| DEFA14A | 2024-09-11 | 2024-09-11 | View Filing |
| DEFA14A | 2024-09-09 | 2024-09-09 | View Filing |
| DEF 14A | 2024-08-14 | 2024-08-14 | View Filing |
| 10-Q | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-08-14 | 2024-08-14 | View Filing |
| EFFECT | 2024-08-14 | 2024-08-14 | View Filing |
| 4 | 2024-08-12 | 2024-08-12 | View Filing |
| 4 | 2024-08-12 | 2024-08-12 | View Filing |
| 4 | 2024-08-12 | 2024-08-12 | View Filing |
| POS AM | 2024-08-09 | 2024-08-09 | View Filing |
| 8-K | 2024-08-06 | 2024-08-06 | View Filing |
| PRE 14A | 2024-08-02 | 2024-08-02 | View Filing |
| 8-K | 2024-07-22 | 2024-07-22 | View Filing |
| EFFECT | 2024-07-22 | 2024-07-22 | View Filing |
| 424B3 | 2024-07-19 | 2024-07-19 | View Filing |
| S-1/A | 2024-07-17 | 2024-07-17 | View Filing |
| S-1/A | 2024-06-26 | 2024-06-26 | View Filing |
| 8-K | 2024-06-26 | 2024-06-26 | View Filing |
| 8-K | 2024-06-21 | 2024-06-21 | View Filing |
| S-1 | 2024-06-07 | 2024-06-07 | View Filing |
| 8-K | 2024-05-31 | 2024-05-31 | View Filing |
| 10-Q | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-05-10 | 2024-05-10 | View Filing |
| ARS | 2024-04-26 | 2024-04-26 | View Filing |
| DEFA14A | 2024-04-26 | 2024-04-26 | View Filing |
| DEF 14A | 2024-04-26 | 2024-04-26 | View Filing |
| 8-K | 2024-04-05 | 2024-04-05 | View Filing |
| 8-K | 2024-03-29 | 2024-03-29 | View Filing |
| 10-K | 2024-03-28 | 2024-03-28 | View Filing |
| 8-K | 2024-03-06 | 2024-03-06 | View Filing |
| SC 13G | 2024-01-31 | 2024-01-31 | View Filing |
| 8-K | 2024-01-30 | 2024-01-30 | View Filing |
| 8-K | 2024-01-30 | 2024-01-30 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Swarm Intelligence Strategy | 66.31% | 1 | 902 | 0.03 | 0.06 | 83.65 |
| Genetic Strat | 38.07% | 1 | 902 | 0.02 | 0.03 | 55.41 |
| Larry Williams PercentR Strategy | 33.11% | 0.99 | 206 | 0.02 | 0.07 | 50.45 |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |